Pfizer is an attractive value play, trading at a significant discount despite strong profitability and growth fundamentals ...

Pfizer Inc (NYSE:PFE) shares are moving higher Tuesday following multiple developments. Here's a look at what's going on.

For Pfizer, the consensus sales estimate for the current quarter of $17.5 billion indicates a year-over-year change of +22.8%. For the current and next fiscal years, $63.36 billion and $62.98 ...

Although the immediate market response was negative, most pharmaceutical stocks recovered after Wall Street analysts ...

The stock's fall snapped a four-day winning streak.

Pfizer (PFE) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.

But I actually see this as a risk factor since according to my earlier analysis, Pfizer ... company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is ...

Last year was a strong one in terms of performance and execution by Pfizer, even though its stock took a hit in 2023 due to a decline in revenues and profits. It saw improved performance of its ...

Pfizer’s PFE $13.7 billion in revenue (an ... Management said that full-year performance is trending toward the high end of EPS guidance. Cardiomyopathy drugs including Vyndaqel grew 31% ...

Shares of Pfizer jumped by as much as 11 percent to Rs 4,995 apiece on May 20 after the company posted a strong performance for the March quarter (Q4FY25). In the past month, this pharma stock ...